ANIP
ANI Pharmaceuticals, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$71.20
−1.09%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 978.4M | 883.4M | 614.4M | 486.8M | 316.4M |
| Cost of Revenue | 340.2M | 432.7M | 250.2M | 181.5M | 138.8M |
| Gross Profit | 638.2M | 450.6M | 364.2M | 305.3M | 177.6M |
| Operating Expenses | |||||
| R&D Expense | 49.9M | 51.7M | 44.6M | 34.3M | 22.3M |
| SG&A Expense | 324.8M | 317.7M | 249.6M | 161.7M | 124.0M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 113.4M | — | 69.4M | 62.3M | 66.5M |
| Total Operating Expenses | 488.0M | 369.4M | 363.6M | 258.3M | 212.9M |
| Cost and Expenses | 828.2M | 802.1M | 613.8M | 439.8M | 351.7M |
| Operating Income (EBIT) | 150.2M | 81.2M | 584.0K | 47.0M | (35.3M) |
| Non-Operating | |||||
| Interest Income | 5.4M | — | — | — | — |
| Interest Expense | 27.4M | 20.1M | 17.6M | 26.9M | 28.1M |
| Net Interest Income | (22.0M) | (20.1M) | (17.6M) | (26.9M) | (28.1M) |
| Other Non-Op Income/Expense | (7.6M) | 14.6M | (22.8M) | (27.1M) | (27.4M) |
| Non-Operating Income (excl Interest) | (19.9M) | (34.6M) | 5.2M | 159.0K | (670.0K) |
| EBT (Pre-Tax Income) | 142.6M | 95.8M | (22.2M) | 19.9M | (62.7M) |
| Income Tax Expense | 34.3M | 17.5M | (3.7M) | 1.1M | (14.8M) |
| Bottom Line | |||||
| Net Income | 105.8M | 78.3M | (18.5M) | 18.8M | (47.9M) |
| Earnings from Cont. Ops | 108.3M | 78.3M | (18.5M) | 18.8M | (47.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 100.0M | 70.6M | (20.1M) | 17.2M | (49.5M) |
| Per Share | |||||
| Basic EPS | $4.83 | $3.50 | ($1.04) | $0.95 | ($3.05) |
| Diluted EPS | $4.63 | $3.32 | ($1.04) | $0.94 | ($3.05) |
| Revenue Per Share | $46.24 | $44.05 | $31.80 | $27.04 | $19.46 |
| Shares | |||||
| Basic Shares Outstanding | 21.2M | 20.1M | 19.3M | 18.0M | 16.3M |
| Diluted Shares Outstanding | 21.9M | 21.2M | 19.3M | 18.2M | 16.3M |
| Profitability Metrics | |||||
| EBITDA | 255.8M | 207.3M | 63.1M | 106.6M | 25.0M |
| D&A | 85.8M | 91.4M | 67.7M | 59.8M | 59.7M |
| EBIT | 170.0M | 115.9M | (4.6M) | 46.8M | (34.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026